Single-dose HPV vaccination is more effective than multi-dose regimens for global cancer prevention
Source: Rivka Galchen. "One Vaccine-Schedule Change That Actually Makes Sense | The New Yorker." February 23, 2026. www.newyorker.com
The Gist
The author argues that giving just one HPV vaccine shot instead of two or three is actually better for preventing cervical cancer worldwide. Even though this change happened during a time when other vaccines were being removed from schedules, the single-shot approach gets many more girls vaccinated, which prevents more cancer cases overall than the old multi-shot system.
Conclusion
The shift to a single-dose HPV vaccine regimen, despite occurring amid problematic vaccine policy changes, represents a significant improvement that will prevent more cervical cancer cases globally than the previous multi-dose approach
Premises
- In 19 countries that switched to single-dose HPV vaccination, 18.5 million additional girls were vaccinated, preventing an estimated 300,000 cervical cancer cases
- Clinical trials showed that single-dose HPV vaccination produces antibody levels nine times higher than natural infection and maintains equal efficacy to multi-dose regimens years later
- Multi-dose vaccination requirements create significant barriers to completion, with only about 80% of participants in trials receiving all doses due to various factors including pregnancy and logistical challenges
- Cervical cancer is the fourth most common cancer in women globally and second only to breast cancer in countries like India and Kenya, making vaccination access crucial
- HPV vaccine costs are prohibitive for low- and middle-income countries where cervical cancer burden is highest, making simplified dosing schedules economically important
- Historical vaccine skepticism and cultural barriers around sexually transmitted infection prevention make simpler vaccination schedules more practically achievable
Assumptions
- Single-dose efficacy data from trials will translate to real-world population-level protection
- Increased vaccination coverage outweighs any potential reduction in individual protection from fewer doses
- The primary barrier to HPV vaccination is logistical complexity rather than fundamental vaccine hesitancy
- Cost and accessibility are more important factors than maximizing individual immune response